Skip to main content

Osteoporose – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung

  • Chapter
  • First Online:
Prävention und Gesundheitsförderung

Part of the book series: Springer Reference Pflege – Therapie – Gesundheit ((SRPTG))

  • 42k Accesses

Zusammenfassung

Die Osteoporose ist eine systemische Skeletterkrankung, die durch eine niedrige Knochenmasse und eine mikroarchitektonische Verschlechterung des Knochengewebes charakterisiert ist. Dies resultiert in einer erhöhten Fragilität des Knochens und in einer erhöhten Frakturhäufigkeit. Sind bereits eine oder mehrere Frakturen als Folge der Osteoporose aufgetreten, liegt eine manifeste Osteoporose vor. Die klinische Bedeutung der Osteoporose liegt im Auftreten von Knochenbrüchen und deren Folgen. Die Diagnose einer Osteoporose basiert auf einer Evaluation von Risikofaktoren, wie z. B. vorbestehende Frakturen oder eine niedrige Knochendichte. Zusätzlich tragen extraossäre Faktoren, wie z. B. Stürze, oder sekundäre Ursachen wesentlich zur vermehrten Knochenbrüchigkeit bei einer Osteoporose bei. Eine adäquate Diagnostik mit der Erfassung der Risikofaktoren ist die Basis für eine korrekte, leitlinienorientierte Therapie der Patienten. Neben einem breiten Angebot an pharmakologischen Interventionen zur individuellen und evidenzbasierten Behandlung der Osteoporose haben sich in den letzten Jahren effiziente Versorgungsstrukturen, gerade für Patienten nach einer osteoporotischen Fraktur, etabliert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 239.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16–35

    Article  CAS  PubMed  Google Scholar 

  • Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334

    Article  PubMed  Google Scholar 

  • Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259

    Article  CAS  PubMed  Google Scholar 

  • Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  • Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254

    Article  CAS  PubMed  Google Scholar 

  • Chang KP, Center JR, Nguyen TV, Eisman JA (2004) Incidenceof hip and other osteoporotic fractures in elderly men andwomen: dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 19:532–536

    Article  PubMed  Google Scholar 

  • Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650

    Article  Google Scholar 

  • Cosman F, Crittenden DB, Grauer A (2017) Romosozumab treatment in post menopausal osteoporosis. N Engl J Med 376:396–397

    PubMed  Google Scholar 

  • Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798

    Article  CAS  PubMed  Google Scholar 

  • DMAB, McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480–1486

    Article  CAS  Google Scholar 

  • DVO Leitlinie (2017) Website: www.dv-osteologie.org/uploads/leitlinie2017

  • Eekman DA, van Helden SH, Huisman AM, Verhaar HJ, Bultink IE, Geusens PP, Lips P, Lems WF (2014) Optimizing fracture prevention: the fracture liaison service, an observational study. Osteoporos Int 25:701–709

    Article  CAS  PubMed  Google Scholar 

  • Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778

    Article  CAS  PubMed  Google Scholar 

  • Fitzpatrick LA (2002) Secondary causes of osteoporosis. Mayo Clin Proc 77:453–446

    Article  PubMed  Google Scholar 

  • Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE (2006) Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 19:189–199

    Article  CAS  PubMed  Google Scholar 

  • Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148

    Article  CAS  PubMed  Google Scholar 

  • Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305

    Article  CAS  PubMed  Google Scholar 

  • Hadji P, Klein S, Gothe H, Häussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) The epidemiology of osteoporosis – Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Ärztebl Int 110(4):52–57

    PubMed  PubMed Central  Google Scholar 

  • Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380–390

    Article  PubMed  PubMed Central  Google Scholar 

  • Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L (2012) Male osteoporosis: a review. World J Orthop 3:223–234

    Article  PubMed  PubMed Central  Google Scholar 

  • Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382–4389

    Article  CAS  PubMed  Google Scholar 

  • International Osteoporosis Foundation. Capture the fracture: fracture liason services. http://www.capturethefracture.org/fracture-liaison-services. Zugegriffen am 22.06.2016

  • IOF Bericht (2013) Hernlund, Kanis et al. Osteoporosis in the EU: medical management, epidemionology and economic burden. Arch Osteoporosis 8:136

    Google Scholar 

  • Jiang HX, Majumdar SR, Dick DA, Moreau M, Raso J, Otto DD, Johnston DW (2005) Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patientswith hip fractures. J Bone Miner Res 20:494–500

    Article  CAS  PubMed  Google Scholar 

  • Kanis JA (1994) on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Printed by the University of Sheffield. World Health Organization: assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series 843. WHO, Geneva

    Google Scholar 

  • Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995

    Article  CAS  PubMed  Google Scholar 

  • Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Möricke PGR, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicenter, double-blind, double-dummy, randomized controlled Trial. Lancet 391:230–240

    Article  CAS  PubMed  Google Scholar 

  • Khosla S (2010) Update in male osteoporosis. J Clin Endocrinol Metab 95:3–10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    Article  CAS  PubMed  Google Scholar 

  • Lambert JK, Zaidi M, Mechanick JI (2011) Male osteoporosis: epidemiology and the pathogenesis of aging bones. Curr Osteoporos Rep 9:229–236

    Article  PubMed  Google Scholar 

  • Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–468

    Article  CAS  PubMed  Google Scholar 

  • Mitchell PJ, Chem C (2013) Secondary prevention and estimation of fracture risk. Best Pract Res Clin Rheumatol 27:789–803

    Article  PubMed  Google Scholar 

  • Murray AW, McQuillan C, Kennon B, Gallacher SJ (2005) Osteoporosis risk assessment and treatment intervention after hip or shoulder fracture. A comparison of two centres in the United Kingdom. Injury 36:1080–1084

    Article  CAS  PubMed  Google Scholar 

  • Nakayama A, Major G, Holliday E, Attia J, Bogduk N (2016) Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 27:873–879

    Article  CAS  PubMed  Google Scholar 

  • Painter SE, Kleerekoper M, Camacho PM (2006) Secondary osteo porosis: a review of the recent evidence. Endocr Pract 12:436–445

    Article  PubMed  Google Scholar 

  • Pinkerton JV, Thomas S (2014) Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol 142:142–154

    Article  CAS  PubMed  Google Scholar 

  • Resch H, Trubrich A, Kocijan R et al (2011) Denosumab – the RANKL-antibody as an example of the biotechnological development. Osteologie 20:203–210

    Article  Google Scholar 

  • Rizzoli R (2014) Nutritional aspects of bone health. Best Pract Res Clin Endocrinol Metab 28:795–808

    Article  CAS  PubMed  Google Scholar 

  • Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22:373–390

    Article  CAS  PubMed  Google Scholar 

  • Rizzoli R, Stevenson JC, Bauer JM, van Loon LJ, Walrand S, Kani JA, Cooper C, Brandi ML, Diez-Perez A, Reginster JY, Task Force ESCEO (2014) The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas 79:122–132

    Article  CAS  PubMed  Google Scholar 

  • Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women withosteoporosis. N Engl J Med 377:1417–1427

    Article  CAS  PubMed  Google Scholar 

  • Shepherd JA, Schousboe JT, Broy SB, Engelke K, Leslie WD (2015) Executive summary of the 2015 ISCD position development conference on advanced measures from DXA and QCT: fracture prediction beyond BMD. J Clin Densitom 18:274–286

    Article  PubMed  Google Scholar 

  • Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M (2002) Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431–4437

    Article  CAS  PubMed  Google Scholar 

  • Tian X, Jee WS, Li X et al (2011) Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimbimmobilization rat model. Bone 48(2):197–201

    Article  CAS  PubMed  Google Scholar 

  • Weinstein RS (2011) Clinical practice: glucocorticoid-induced bone disease. N Engl J Med 365:62–70

    Article  CAS  PubMed  Google Scholar 

  • Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E (2010) Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375:1729–1736

    Article  PubMed  Google Scholar 

  • Zhou J, Ma X, Wang T, Zhai S (2016) Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int 27:3289–3300

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andreas Kurth .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kurth, A. (2021). Osteoporose – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. In: Tiemann, M., Mohokum, M. (eds) Prävention und Gesundheitsförderung. Springer Reference Pflege – Therapie – Gesundheit . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62426-5_51

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62426-5_51

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62425-8

  • Online ISBN: 978-3-662-62426-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics